MK-4716-001 Clinical Trial
Phase 1
250
about 5 years
18+
3 sites in NJ, TX, VA
About this study
This trial is testing a treatment called MK-4716 in people with certain solid tumors. Researchers are looking to see if this treatment is safe and well-tolerated when used alone or with other treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Cetuximab
- 2.Receive Pembrolizumab
- 3.Take MK-4716
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cetuximab, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
injection (Injection), infusion
Primary: Number of Participants Who Discontinue Study Intervention Due to an AE, Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLT), Number of Participants Who Experience an Adverse Event (AE)
Secondary: Area Under the Concentration-Time Curve (AUC) of MK-4716, Half-Life (t1/2) of MK-4716, Maximum Plasma Concentration (Cmax) of MK-4716
Oncology